|Table of Contents|

Research status of PD-1 and PD-L1 inhibitors in the treatment of prostate cancer

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2023 12
Page:
2357-2363
Research Field:
Publishing date:

Info

Title:
Research status of PD-1 and PD-L1 inhibitors in the treatment of prostate cancer
Author(s):
WU Haichao; DING Mingxia; CHEN Zhenjie; LIN Jiawei; HE Zexi; GU Jun
Department of Urology,the Second Affiliated Hospital of Kunming Medical University,Yunnan Kunming 650101,China.
Keywords:
prostate cancer; PD-1; PD-L1; immunotherapy
PACS:
R737.25
DOI:
10.3969/j.issn.1672-4992.2023.12.033
Abstract:
Prostate cancer is a common malignant tumor in men.The current main treatments are radical prostatectomy (RP) and androgen deprivation therapy (ADT),but both have their own limitations.In recent years,immunotherapy has developed rapidly.Among them,programmed cell death-1 (PD-1) and programmed cell death-ligand 1 (PD-L1) are ideal targets for immunotherapy,and their inhibitors have played an increasingly important role in the treatment of lung cancer,colon cancer and other cancers.With the progress and in-depth research of PD-1/PD-L1 in prostate cancer,its mechanism of action in prostate cancer has gradually become clear,and PD-1/PD-L1 inhibitors will also have a broad scope prospects for the treatment of prostate cancer.This article will review the expression,mechanism of action of PD-1 and PD-L1 in prostate cancer and related research progress of its inhibitors in the treatment of prostate cancer.

References:

[1]FERLAY J,COLOMBET M,SOERJOMATARAM I,et al.Estimating the global cancer incidence and mortality in 2018:GLOBOCAN sources and methods［J］.Int J Cancer,2019,144(8):1941-1953.
[2]SCHWEIZER MT,DRAKE CG.Immunotherapy for prostate cancer:recent developments and future challenges［J］.Cancer Metastasis Rev,2014,33(2-3):641-655.
[3]BASTAKI S,IRANDOUST M,AHMADI A,et al.PD-L1/PD-1 axis as a potent therapeutic target in breast cancer［J］.Life Sci,2020,247:117437.
[4]SCIMECA M,BONFIGLIO R,URBANO N,et al.Programmed death ligand 1 expression in prostate cancer cells is associated with deep changes of the tumor inflammatory infiltrate composition［J］.Urologic Oncology:Seminars and Original Investigations,2019,37(5):297.e19-297.e31.
[5]杨志群.PD-1/PD-L1免疫检查点抑制剂在肿瘤免疫治疗中的应用现状［J］.实用临床医学,2019,20(12):98-102. YANG ZQ.Application of PD-1/PD-L1 immune checkpointinhibitors in tumor immunotherapy［J］.Practical Clinical Medicine,2019,20(12):98-102.
[6]GEVENSLEBEN H,DIETRICH D,GOLLETZ C,et al.The immune checkpoint regulator PD-L1 is highly expressed in aggressive primary prostate cancer［J］.Clin Cancer Res,2016,22(8):1969-1977.
[7]PETITPREZ F,FOSSATI N,VANO Y,et al.PD-L1 expression and CD8+ T-cell infiltrate are associated with clinical progression in patients with node-positive prostate cancer［J］.European Urology Focus,2019,5(2):192-196.
[8]MO RJ,HAN ZD,LIANG YK,et al.Expression of PD-L1 in tumor-associated nerves correlates with reduced CD8+ tumor-associated lymphocytes and poor prognosis in prostate cancer［J］.International Journal of Cancer,2019,144(12):3099-3110.
[9]KWEK SS,LEWIS J,ZHANG L,et al.Preexisting levels of CD4 T cells expressing PD-1 are related to overall survival in prostate cancer patients treated with ipilimumab［J］.Cancer Immunol Res,2015,3(9):1008-1016.
[10]XU LJ,MA Q,ZHU J,et al.Combined inhibition of JAK1,2/Stat3/PD-L1 signaling pathway suppresses the immune escape of castration-resistant prostate cancer to NK cells in hypoxia［J］.Mol Med Rep,2018,17(6):8111-8120.
[11]GOPALAKRISHNAN D,KOSHKIN VS,ORNSTEIN MC,et al.Immune checkpoint inhibitors in urothelial cancer:recent updates and future outlook［J］.Ther Clin Risk Manag,2018,14:1019-1040.
[12]BRAHMER JR,DRAKE CG,WOLLNER I,et al.Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors:safety,clinical activity,pharmacodynamics,and immunologic correlates［J］.Journal of Clinical Oncology,2010,28(19):3167-3175.
[13]TOPALIAN SL,HODI FS,BRAHMER JR,et al.Safety,activity,and immune correlates of anti-PD-1 antibody in cancer［J］.N Engl J Med,2012,366(26):2443-2454.
[14]SHARMA P,PACHYNSKI RK,NARAYAN V,et al.Nivolumab plus ipilimumab for metastatic castration-resistant prostate cancer:preliminary analysis of patients in the CheckMate 650 trial［J］.Cancer Cell,2020,38(4):489-499.
[15]TUTHILL M,CAPPUCCINI F,CARTER L,et al.Results from ADVANCE:A phase I/II open-label non-randomised safety and efficacy study of the viral vectored ChAdOx1-MVA 5T4 (VTP-800) vaccine in combination with PD-1 checkpoint blockade in metastatic prostate cancer［J］.Annals of Oncology,2020,31(4):S543.
[16]YUAN Z,FERNANDEZ D,DHILLON J,et al.Proof-of-principle Phase I results of combining nivolumab with brachytherapy and external beam radiation therapy for Grade Group 5 prostate cancer:safety,feasibility,and exploratory analysis［J］.Prostate Cancer Prostatic Dis,2020,24(1):140-149.
[17]HANSEN AR,MASSARD C,OTT PA,et al.Pembrolizumab for advanced prostate adenocarcinoma:findings of the KEYNOTE-028 study［J］.Annals of Oncology,2018,29(8):1807-1813.
[18]ANTONARAKIS ES,PIULATS JM,GROSS-GOUPIL M,et al.Pembrolizumab for treatment-refractory metastatic castration-resistant prostate cancer:multicohort,open-label phase II KEYNOTE-199 study［J］.J Clin Oncol,2020,38(5):395-405.
[19]TUCKER MD,ZHU J,MARIN D,et al.Pembrolizumab in men with heavily treated metastatic castrate-resistant prostate cancer［J］.Cancer Medicine,2019,8(10):4644-4655.
[20]YU EY,PIULATS JM,GRAVIS G,et al.Pembrolizumab (pembro) plus olaparib in patients (pts) with docetaxel-pretreated metastatic castration-resistant prostate cancer (mCRPC):KEYNOTE-365 cohort A efficacy,safety,and biomarker results［J］.Journal of Clinical Oncology,2020,38(15):S5544.
[21]KOLINSKY MP,GRAVIS G,MOUREY L,et al.Pembrolizumab (pembro) plus docetaxel and prednisone in patients (pts) with abiraterone acetate (abi) or enzalutamide (enza)-pretreated metastatic castration-resistant prostate cancer (mCRPC):KEYNOTE-365 cohort B efficacy,safety and,biomarker results［J］.Journal of Clinical Oncology,2020,38(15):S5550.
[22]BERRY WR,FONG PCC,PIULATS JM,et al.Pembrolizumab (pembro) plus enzalutamide (enza) in patients (pts) with abiraterone acetate (abi)-pretreated metastatic castration-resistant prostate cancer (mCRPC):KEYNOTE-365 cohort C efficacy,safety,and biomarker results［J］.Journal of Clinical Oncology,2020,38(15):5545.
[23]ROSS AE,HURLEY PJ,TRAN PT,et al.A pilot trial of pembrolizumab plus prostatic cryotherapy for men with newly diagnosed oligometastatic hormone-sensitive prostate cancer［J］.Prostate Cancer and Prostatic Diseases,2019,23(1):184-193.
[24]HOTTE SJ,WINQUIST E,CHI KN,et al.CCTG IND 232:A phase II study of durvalumab with or without tremelimumab in patients with metastatic castration resistant prostate cancer (mCRPC)［J］.Annals of Oncology,2019,30(5):v885.
[25]KARZAI F,MADAN RA,OWENS H,et al.A phase 2 study of olaparib and durvalumab in metastatic castrate-resistant prostate cancer (mCRPC) in an unselected population［J］.Journal of Clinical Oncology,2018,36(6):S163.
[26]LIM EA,BAUER TM,PATEL MR,et al.A phase I,open-label,multicenter study to assess the safety,pharmacokinetics,and preliminary antitumor activity of AZD4635 both as monotherapy and in combination in patients with advanced solid malignancies:Results from prostate cancer patients (NCT02740985)［J］.Journal of Clinical Oncology,2020,38(15):S5518.
[27]PORTER I,EADE T,KNEEBONE A,et al.A phase II,open-label study of durvalumab in combination with stereotactic body radiotherapy in androgen-intact patients with oligometastatic prostate cancer［J］.Journal of Clinical Oncology,2020,38(6):S263.
[28]FUMET JD,LIMAGNE E,THIBAUDIN M,et al.Precision medicine phase II study evaluating the efficacy of a double immunotherapy by durvalumab and tremelimumab combined with olaparib in patients with solid cancers and carriers of homologous recombination repair genes mutation in response or stable after olaparib treatment［J］.BMC Cancer,2020,20(1):748.
[29]AGARWAL N,LORIOT Y,MCGREGOR B A,et al.Cabozantinib (C) in combination with atezolizumab (A) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC):Results of cohort 6 of the COSMIC-021 study［J］.Journal of Clinical Oncology,2020,38(6):S139.
[30]KIM VM,BLAIR AB,LAUER P,et al.Anti-pancreatic tumor efficacy of a Listeria-based,Annexin A2-targeting immunotherapy in combination with anti-PD-1 antibodies［J］.J Immunother Cancer,2019,7(1):132.
[31]GUO ZS,LU B,GUO Z,et al.Vaccinia virus-mediated cancer immunotherapy:cancer vaccines and oncolytics［J］.J Immunother Cancer,2019,7(1):6.
[32]ZHOU Q,WANG Y,MA W.The progress of immunotherapy for glioblastoma［J］.Hum Vaccin Immunother,2015,11(11):2654-2658.
[33]DORFF TB,ACOBA JD,PAL SK,et al.Assessing different sequencing regimens of atezolizumab (atezo) and sipuleucel-T (sipT) in patients who have asymptomatic or minimally symptomatic metastatic castrate-resistant prostate cancer［J］.Journal of Clinical Oncology,2020,38(6):S141.
[34]GILLESSEN SOMMER S,POWLES T,DRAKE C,et al.IMbassador250:A phase III trial in patients with metastatic castration-resistant prostate cancer (mCRPC) comparing atezolizumab plus enzalutamide vs enzalutamide alone［J］.European Urology,Supplements,2018,17(2):e1155.
[35]FONG L,MORRIS M,ARMSTRONG A,et al.A phase Ib trial to study the safety and tolerability of atezolizumab with radium-223 dichloride in patients with metastatic castrateresistant prostate cancer (mCRPC)［J］.Cancer Research,2017,77(13):1.
[36]BRYCE AH,DRONCA RS,COSTELLO BA,et al.PT-112 in advanced metastatic castrate-resistant prostate cancer (mCRPC),as monotherapy or in combination with PD-L1 inhibitor avelumab:Findings from two phase I studies［J］.Journal of Clinical Oncology,2020,38(6):S83.
[37]WONG RL,YU EY.Refining Immuno-oncology approaches in metastatic prostate cancer:transcending current limitations［J］.Current Treatment Options in Oncology,2021,22(2):13.
[38]GRAHAM LS,MONTGOMERY B,CHENG HH,et al.Mismatch repair deficiency in metastatic prostate cancer:Response to PD-1 blockade and standard therapies［J］.PLoS One,2020,15(5):e0233260.
[39]DUDEK AZ,LIU LC,GUPTA S,et al.Phase Ib/II clinical trial of pembrolizumab with bevacizumab for metastatic renal cell carcinoma:BTCRC-GU14-003［J］.Journal of Clinical Oncology,2020,38(11):1138-1145.

Memo

Memo:
云南省科技厅科技计划项目（昆医联合专项）［编号：2019FE001(-226)］；云南省医学领军人才项目（编号：L-2018009）；昆明医科大学研究生创新基金（编号：2021S058）
Last Update: 1900-01-01